Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Patented DehydraTECH(TM) Technology’s Effectiveness on GLP-1 Drugs for Potential Diabetes Treatment and Weight Loss

Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better
Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A22-1 animal study, which yielded weight loss, and improved triglyceride and cholesterol levels among diabetic-conditioned animals
The company plans to replicate the results from this study while also exploring ways to improve the overall bioavailability of GLP-1 drugs for diabetes treatment and weight loss
Lexaria management is optimistic that it will build on previous studies, replicate previous positive results, and improve the overall efficacy of GLP-1 drugs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced plans to launch new human and animal studies that seek to examine its patented DehydraTECH(TM) technology’s potential on GLP-1 drugs for the treatment of diabetes and weight loss. This announcement follows the recent study results published on “New England Journal of Medicine,” which showed that 49 to 52 pounds weight loss was a common outcome across the 2,539 adult study participants (https://cnw.fm/bP9IJ).

DehydraTECH has demonstrated, in many instances, significant improvement in how active pharmaceutical ingredients (“APIs”) enter the bloodstream with its strong bioavailability enhancing capabilities. Its unique and revolutionary approach has seen Lexaria granted 37 patents for the technology, ultimately safeguarding its applicability, given its growing list of applications ranging from nicotine delivery to NSAIDs, antiviral drugs, cannabinoids, vitamins, and more.

So far, DehydraTECH has demonstrated positive results in diabetes-related studies. Its DIAB-A22-1 animal study yielded at least three positive outcomes: weight loss plus improved triglyceride and cholesterol levels. Reduced body weight, specifically, was realized in just four days after the start of dosing with DehydraTECH-CBD, with peak results achieved nine days after dosing and maintained throughout the 8-week study duration (https://cnw.fm/wfWYV).

Lexaria looks to replicate these results with GLP-1 drugs while also exploring ways to make these drugs better. GLP-1 agonists have been known to help manage blood sugar levels in people with type 2 diabetes. They have also proven effective in treating obesity, a result which has been very much welcomed by consumers and the more than 37 million Americans currently living with diabetes. By doing so, Lexaria looks to carve out a significant market share in the diabetes drug market, projected to hit $82.93 billion in value by 2027 (https://cnw.fm/W7taU).

This commitment builds on the work that Lexaria has been doing with DehydraTECH since 2014. It also reflects the technology’s potential and the company’s confidence in it. Thus far, studies have shown exceptional results, asserting Lexaria as a dominant figure in the drug delivery technology space. Its management is optimistic that as it heads into GLP-1 research, it will build on its previous studies, ultimately improving the overall efficacy of GLP-1 drugs and further demonstrating DehydraTECH’s potential.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Increase in Traffic Fatalities in Prohibitionist States, Drop Where Cannabis Is Legal

A new study from Quartz Advisor has found states that legalized cannabis since 2016 registered a “meaningful decline” in traffic fatalities. Interestingly, the paper found that states that have continued to criminalize cannabis possession and use have seen a slight increase in traffic fatalities.

The study goes against the notion that legalizing cannabis would lead to higher rates of driving under the influence and result in more traffic fatalities. While prohibitionists argued that legalizing cannabis would prove to be a danger to the public, this study suggests that ending cannabis prohibition may have a connection with fewer traffic accidents and fatalities.

Researchers concluded that traffic safety shouldn’t be a major concern for cannabis reform initiatives, especially when compared to alcohol, which has much higher traffic accident and fatality rates. They noted that while there has been no evidence connecting cannabis reform with a statistically significant rise in traffic fatalities, alcohol remains widely available despite its role in traffic accidents.

The report relied on traffic fatality data collected from four states — Maine, California, Nevada and Massachusetts — from 2016 to 2019. It then compared this data to national average rates and traffic fatality states in Wyoming, Kansas, Indiana, Nebraska and Idaho, all states where cannabis was illegal.

None of the four states with legal cannabis markets registered an increase in traffic deaths, the paper says. In fact, three of them reported a “significant decrease” in traffic deaths over the study period. Massachusetts saw the largest drop in traffic fatalities (28.6%) while Maine didn’t register any change in traffic deaths.

All four states saw a combined 11.6% drop in traffic fatalities from 2016 to 2019, 1.0% more than the decline in average traffic deaths during the same period (10.6%). The five states without legal cannabis markets registered a 1.7% increase in combined traffic deaths from 2016 to 2019.

However, when the researchers included data from 2020–2021, the traffic death rate for states with cannabis markets went up by 6.0% while states without legal cannabis markets saw a 0.7% reduction in traffic fatalities. Researchers say they excluded data from 2020 and 2021 as the two years ‘were anomalies’ in traffic accident trends.

Traffic fatalities spiked by 18.9% nationally from 2019–2020 after decades of decline while cannabis states saw a 19.9% increase in 2016 and noncannabis states registered a 2.3 decline in traffic fatalities over the same period.

The broader cannabis industry and its main actors such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) is likely to welcome these findings because they dispel the misconception that marijuana legalization results in an increase in road traffic accidents and fatalities.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Minnesota University-Led Study Uncovers Medical Marijuana Usage Patterns

Research led by the University of Minnesota in partnership with Vireo Health looked into patterns of medical marijuana consumption and use. Currently, the medical use of marijuana is legal in 38 states in the United States, the federal District of Columbia and 4 inhabited territories.

Despite the rising use of medical marijuana, state-cannabis programs don’t have consistent guidelines governing products being consumed by patients, particularly for THC and CBD. CBD (cannabidiol) and THC (tetrahydrocannabinol) are the two primary compounds found in marijuana. While THC does induce a high when consumed, CBD does not.

Both compounds interact with the body differently, which means that side effects and symptom control varies from one individual to another.

The absence of standardized procedures in state programs makes it hard to forecast how patients may respond to these alternative treatments, especially when one considers that most patients may have comorbidities and highly variable interactions with their other treatments.

The study’s lead author, Professor Angela Birnbaum, stated that past data showed that THC and CBD concentrations in the blood could vary extensively among patients and could cause unanticipated side effects and varied responses.

For their study, the researchers conducted an analysis of data collected from about 50% of all registered users of medical marijuana in the state of Minnesota in the period between June 2016 and November 2019. All users included were also part of Vireo Health’s program.

The researchers then examined the THC and CBD content of products provided and dosing of patients, finding that about 60% of patients who received medical marijuana had indications of severe pain. Given that they were the largest patient population, the researchers observed huge differences in dosages between younger and older adults with similar diagnosis, which brings into question the factors that contributed to varied dosages.

Additionally, the researchers found that most patients used drugs that contained both THC and CBD, despite evidence showing that CBD was effective in seizure prevention in patients with epilepsy. From the study’s findings, one can see that the data provided shows that major cannabinoid quantities, doses received and choice of product is mostly based on patient preference and pharmacist selection rather than a physician’s prescription.

In the report, Birnbaum noted that more studies were needed to understand the long-term influence of marijuana use, particularly in older adults who were typically on more than one medication and had a heightened potential for drug-drug interactions. This research was funded by the University of Minnesota Medical Discovery Team on Addiction’s Pilot Grant and the MacMillan Innovative Epilepsy Research and Education Fund.

These studies will most likely give cannabis entities such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) plenty to think about as they plan how best to reach different categories of patients with their medical cannabis products.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Georgia Pharmacies Start Selling Medical Marijuana Oil

Oct. 27, 2023, marked the first day of medical cannabis sales at independent pharmacies in Georgia, with Robin’s Pharmacy, Allen Pharmacy Group and Omega Pharmacy becoming the first to secure state licenses for the sale of low-THC (less than 5% concentration) medical cannabis products.

Dr. Ankit Patel of Robins Pharmacy expressed his excitement, calling it a historic moment. He had been closely monitoring the development of the state’s cannabis laws for about four years, eagerly awaiting the opportunity for independent pharmacies to stock these products.

To gain state approval, pharmacies need to undergo inspections by the Georgia Drugs & Narcotics Agency, which assesses security measures and evaluates the staff’s knowledge of handling and dispensing medical marijuana. State law mandates that cannabis products be displayed on shelves alongside other prescription medications.

Bill Posey, owner of Allen Pharmacy Group, likened medical cannabis to other “dangerous” drugs, citing examples such as blood pressure medication that are categorized similarly. Posey’s pharmacy commenced cannabis sales on Oct. 30, 2023, and he reported receiving inquiries from potential customers even before the official sales launch.

Dr. Jordan Day, owner of Omega Pharmacy, expects to initiate medical cannabis sales at her pharmacy in the near future. She envisions her pharmacy playing a crucial role in educating patients about the benefits of medical cannabis, potentially replacing traditional anxiety, pain, and sleep medications.

Georgia’s Access to Medical Cannabis Oil Commission chair, Andrew Turnage, expressed the significance of this development, stating that it would greatly enhance accessibility to medical cannabis for patients across the state as pharmacies are just a short drive away.

The journey to this point began when Governor Brian P. Kemp signed HB 324, known as Georgia’s Hope Act, in April 2019, with the law coming into effect in July of the same year. The measure aimed to provide access to medical marijuana oil for individuals in need, especially those battling chronic and debilitating diseases.

The law entrusted the regulation, production, cultivation, manufacturing and sale of low-THC oil to the Georgia Access to Medical Marijuana Commission. The commission was formed in November 2019, but it wasn’t until July 2021 that the state revamped its medical marijuana program, ultimately approving six companies to sell cannabis.

Recent updates revealed that the number of medical marijuana patients in the state was significantly lower than initially believed. While it was originally thought that there were more than 50,000 patients, anomalies in the system, such as expired patient cards and patient passings since 2015, have now reduced the count to approximately 14,000.

This development is probably welcome news to the entire marijuana industry, including companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) since the availability of cannabis products at pharmacies increases access for those who badly need these products to address their medical needs.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Massachusetts Marijuana Firms Challenge Federal Ban on Cannabis

Last week, an alliance of marijuana companies in the state of Massachusetts filed a lawsuit that challenges the federal prohibition of cannabis as it applies to individual states. Currently, marijuana remains classified as a Schedule I substance under the Controlled Substances Act. This is despite the fact that the medical use of marijuana is legal in 38 states, 4 U.S. territories and the federal District of Columbia. Adult-use marijuana is also legal in 23 states, 3 U.S. territories and D.C.

The Controlled Substances Act was enacted by the 91st United States Congress and signed into law by President Richard Nixon in 1970.

In their suit, the companies argue that the Controlled Substances Act, which prohibits the growing, manufacture, sale and possession of intrastate cannabis, is an unconstitutional ban. They maintain that this act deprives marijuana companies of their rights under the Fifth Amendment by depriving them of liberty without due process and by introducing unlawful and unwarranted federal government intrusion into their businesses.

The coalition has asked that the Massachusetts district court deem the act to be unconstitutional, in their quest for a declaratory judgment. The suit names its sole defendant as U.S. Attorney General Merrick Garland.

The challengers also note that the Controlled Substances Act subverts state cannabis programs, giving the example of the 2012 Massachusetts Medical Marijuana Initiative. During this time, voters in the state opted to legalize medical cannabis. A few years later in 2016, the Massachusetts Marijuana Legalization Initiative was introduced, with voters legalizing recreational cannabis for adults.

The lawsuit states that the comprehensive state regulations protect consumers while also ensuring that the regulated cannabis sold in Massachusetts is distinguishable from illegal, interstate cannabis.

The suit also claims that the Controlled Substances Act harms small and large businesses and threatens public safety. The companies argue that because of this act, marijuana businesses aren’t able to take part in federal programs. It also leads to issues with advertising, hiring, loans, payroll and insurance because most service providers have affiliations with the federal governments.

At the moment, state-regulated marijuana businesses are not allowed to use credit-card processors because financial institutions are regulated by the federal government. By relying on cash, most cannabis businesses have a higher risk of being robbed.

Following the suit’s filing, Verano president Darren Weis, stated that he was honored to be supporting this groundbreaking suit that pushed for equal treatment under the law. Weiss is one of the plaintiffs involved in the suit.

This lawsuit is likely to draw the attention of many cannabis companies that are operating in other jurisdictions such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) since it could have implications for the industry across the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Brazilian Scientists Find Cannabis Compound Inside Unrelated Plant

Researchers have discovered that a common plant in Brazil contains the cannabis ingredient cannabidiol (CBD). This discovery creates new opportunities for the production of the well-known substance from alternative sources.

A group of scientists from the Federal University of Rio de Janeiro uncovered CBD in the flowers and fruits of the Tremamicranthablume (trema) plant, a common shrub found throughout Brazil. According to lead scientist Rodrigo Moura Neto, the plant, which is sometimes categorized as a weed, is a promising source of CBD.

CBD, recognized for its potential in managing anxiety, chronic pain and epilepsy, stands as a key active component in marijuana, alongside tetrahydrocannabinol (THC), which is responsible for inducing the “high” associated with cannabis use.

While CBD’s medicinal efficacy remains under scientific scrutiny, Neto’s chemical analysis confirmed the presence of CBD in trema while ruling out the existence of THC. This development points to the likelihood of discovering additional sources of CBD, evading the legal constraints tethered to marijuana, which remains prohibited in many regions, including Brazil.

“It presents a legal alternative to marijuana use,” said Neto, highlighting the ubiquitous growth of trema throughout Brazil and emphasizing its potential as a more accessible and cost-effective CBD source. He also noted that CBD had previously been found in a related plant in Thailand.

Additionally, a different study published in May 2023 in the “Nature Plants” Journal revealed that the woolly umbrella, a plant native to South Africa, contained more than a dozen different types of cannabinoids. Despite the plant’s inability to produce CBD or THC, researchers did discover notable concentrations of cannabigerolic acid (CBGA), cannabichromene (CBC) and cannabibigerol (CBG).

Although Neto has not yet formally published his findings, he stated that he intends to broaden the study’s emphasis to include improving trema CBD extraction techniques and evaluating the drug’s efficacy in treating patients for ailments that are currently being treated with medicinal cannabis.

The Brazilian government recently awarded his team a grant of 500,000 real ($104,000) to continue the research, which he predicts will take at least five years to finish.

According to a survey conducted last year by market research company Vantage Market Research, the global market for CBD is currently expected to be worth close to $5 billion. The study also predicted that the industry will likely expand to exceed $47 billion by 2028, primarily due to the substance’s increasing popularity in health and wellness.

These research findings could open up new opportunities for the wider cannabis industry, including established actors such as SNDL Inc. (NASDAQ: SNDL), which could explore diversifying their operations.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Cannabis Legalization Causes Major Drug Test Manufacturer to Replace Tests with Fentanyl

Psychemedics, a leading drug-testing technology manufacturer, has unveiled an innovative screening panel that diverges from detecting cannabis, instead focusing on fentanyl and other controlled drugs, as a response to the shifting landscape due to the legalization of cannabis in numerous states.

Psychemedics’ updated Advanced 5-Panel Drug Screen marks a transformative step in how companies safeguard their places of work by shifting focus from cannabis to the major threat posed by fentanyl. The revamped screening panel has garnered approval from the Food & Drug Administration (FDA) and is celebrated for its enhanced accuracy in identifying amphetamines, PCP, opioids and cocaine.

Psychemedics, established in 1987 after which it pioneered hair testing, expressed the necessity for this change in a recent press release and highlighted the failure of the original five-panel drug tests to adapt to the contemporary drug market, specifically in detecting the escalating presence of fentanyl.

Psychedemics CEO and president Brian Hullinger stressed the substantial transformation in workplace challenges brought about by the changing dynamics involving cannabis and fentanyl. He explained how the company responded to this shift by developing its Advanced 5-Panel, aiming to close the existing gap.

With a growing number of states legalizing marijuana, protections have been established for employees who use cannabis during their off-duty hours. In California, for instance, employers are now prohibited from inquiring about an applicant’s prior cannabis use.

Similarly, Michigan recently ceased pre-employment cannabis drug testing for job applicants for government jobs and offered those penalized for past THC tests the chance to have their sanctions retroactively removed. Nevada and Washington also protect job applicants from discrimination based on positive marijuana tests. New York extended job protections for those adults legally using marijuana during their off-hours while away from their workplaces.

At the federal level, there have been attempts to end marijuana drug testing for those applying for federal jobs. The House Rules Committee has repeatedly blocked these efforts, but the Senate approved defense legislation back in July preventing intelligence agencies from withholding security clearances based solely on past cannabis consumption. The House Oversight & Accountability Committee has also approved a bipartisan bill to prevent federal employment or security clearance denials due to past marijuana consumption.

Concurrently, concerns regarding the fentanyl drug supply have grown. While there have been debates over claims of fentanyl-laced cannabis, experts acknowledge the presence of this potent opioid in drugs such as cocaine and heroin.

The spreading wave of legalization isn’t only leading to shifts in the work of makers of testing kits for drugs. It is also creating many opportunities for companies such as Innovative Industrial Properties Inc. (NYSE: IIPR) that don’t deal in the substance but serve cannabis companies in an ancillary role.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Feds Fund Central Research Center to Combat Barriers to Cannabis Research

Recently, the National Institutes of Health posted a funding opportunity notice stating that it sought an eligible body to operate a new center for marijuana and cannabinoid research via a cooperative agreement. The centralized cannabis research center would be designed to help researchers overcome barriers to studying cannabis amid federal prohibition. This is in addition to allowing scientists to generate more scientific evidence across various research domains in clinical and basic research.

Addressing barriers in cannabis research has been a priority for many federal health agencies as researchers continue to be subjected to costly and taxing registration processes in order to access marijuana for research. This is primarily because of the drug’s current status under the Controlled Substances Act.

The NIH noted that ultimately, the research center could facilitate advancements in research through interactions among experts in relevant clinical, commercial, regulatory and basic science areas, both within the research center itself and jointly with other researchers that possess diverse expertise and research backgrounds.

The NIH also outlined central components of the center’s objectives, including research standards, research support and regulatory guidance. On the regulatory front, the center would be charged with organizing meetings with the DEA and/or FDA to obtain updates on regulatory information, among other tasks. On the research standards front, the center would be responsible for the development of research metrics and standards that enhance the rigor of chemical analysis of complex marijuana products to improve research reproducibility, among other functions.

With regard to research support, the research center could identify and circulate early career reviewer opportunities under the NIH, administer seed funding and use social media to transmit scientific information, among other functions. Agencies under the NIH that will occupy supportive roles in the center’s work include the National Center for Complementary and Integrative Health, the National Cancer Institute, the National Institute on Aging and the National Institute on Drug Abuse.

Interested parties must elaborate how they propose to achieve the stipulated objectives, which involve the creation of a clearing house for existing research guidance, developing best practices, organizing meetings with the FDA and the DEA, standardizing research methodologies, circulating relevant scientific literature on marijuana and apportioning seed funding to support research initiatives.

Institutions that are invited to submit applications include nonprofit organizations, universities and local and federal government agencies, among others. The deadline for letters of intent is March 16, 2023, which is also when applications will start being accepted.

If this new research facility works as intended, cannabis industry actors such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) could sooner or later see a decrease in some of the hurdles they face in studying marijuana.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Scientists Discover Little-Known Compounds That Give Marijuana Unique Flavors

Scientists from the American Chemical Society have identified previously undiscovered cannabis compounds that they say are actually responsible for marijuana’s unique flavors. For the longest time, the conventional knowledge has been that chemical compounds called terpenes create the distinctive aromas of different cannabis strains. Marijuana is estimated to contain close to 400 terpenes, but researchers have discovered only around 200 and studied more than a dozen.

Outside of the cannabis plant, there are more than 20,000 known terpenes, which create the unique flavors and aromas of flowers, herbs, fruits and vegetables. As such, the assumption was that terpenes were also responsible for the aromas produced by various marijuana strains. However, the recent American Chemical Society study challenged conventional knowledge through the discovery of previously unknown compounds and raised questions surrounding the true source of marijuana’s varied and unique flavors.

The study involved a research team from cannabis testing and extraction companies. The researchers wrote that the role of terpenes in cannabis aroma variety seemed to be blown out of proportion. Terpenes account for an estimated 1% to 4% of a cured cannabis flower’s total mass, the researchers said, and while the terpenes contribute to the plant’s overall smell, they don’t play a major role in creating the “peculiar aromatic attributes” of different marijuana varieties.

According to the researchers, most of the aromatic information for various cannabis strains comes from flavorants, a group of chemicals encompasses compounds, including alcohol and esters. The researchers say they discovered various “nonterpenoid compounds” upon analyzing 31 samples of ice hash rosin.

They specifically noted a novel group of tropical volatile sulfur compounds (VSCs) that significantly contribute to the strong aroma of tropical fruits such as citrus as well as a highly aromatic compound called skatole (3-methylindole). Flavorants are also largely responsible for exotic scents in Gelato, Skittles, Runts and Apple Fritters.

TJ Martin, the research & development VC of Abstrax, an extraction company, says the research team found a clear connection between previously undiscovered cannabis compounds and the plant’s notoriously pungent aromas. The team found that although terpenes played a role in producing marijuana aromas, they weren’t essential in the differentiation of aromas in various cannabis strains.

Terpenes are often used to differentiate different cannabis varieties, but Abstrax CEO and cofounder Max Coby notes that this often results in inaccurate classifications. Max says the research team’s discovery will play a significant role in the validation of marijuana authenticity as well as the accurate classification of different marijuana varieties.

It wouldn’t be surprising if major marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) provide the detailed flavoring profiles of their future products in order to differentiate their offerings from other products on the market.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa (“EB”). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The abstract title is “INM-755 Cannabinol Cream Demonstrates Anti-Itch Activity in Patients with Epidermolysis Bullosa.” Mancini’s presentation is scheduled to begin at 4:08 p.m. ET on Nov. 7. Designed to evaluate the safety of INM-755 CBN cream, the phase 2 within-patient, double-blind study gathered preliminary evidence of the cream’s efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone. A copy of the poster and other presentation materials will be on the company’s website following the event.

To view the full press release, visit https://cnw.fm/H6gFX

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com